Is BioReference a good company?

Is Bio-Reference Labs a good company to work for? Bio-Reference Labs has an overall rating of 3.7 out of 5, based on over 549 reviews left anonymously by employees.

Is BioReference Lab legit?

With a national footprint and niche market experience, BioReference provides credible and innovative solutions that meet the needs of employers, governmental agencies, educational systems, hospitals and health systems, correctional institutions, sports leagues, travel and leisure industries, and retail markets.

Who owns BioReference Labs?

OPKO Health, Inc.
MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE: OPK) and BioReference Laboratories, Inc. (NASDAQ: BRLI) today announced the completion of the acquisition of BioReference by OPKO. Shareholders of BioReference will receive 2.75 shares of OPKO common stock for each share of BioReference common stock.

How many labs does BioReference have?

10 laboratory locations
The company is in-network with the largest health plans in the United States, serves approximately 19 million patients annually, operates a network of 10 laboratory locations, and is backed by a medical staff of more than 300 M.D., D.O., Ph.

Why did I receive a check from BioReference laboratories?

Why did I receive this bill? The invoice you received is for laboratory services provided by BioReference, which were ordered by your physician. This invoice is for laboratory testing fees only and is separate from any bill you may have received from your physician and/or paid at your physician’s office.

Is BioReference laboratories a public company?

Bio-Reference is the nation’s third largest publicly-traded lab company and had revenue of $832 million for its fiscal year ending October 31, 2014.

When did opko buy Bioreference?

MANY LAB INDUSTRY EXPERTS and Wall Street investors were caught by surprise when, on June 2, they learned that Opko Health Inc., of Miami, Florida, had agreed to pay $1.47 billion in an all-stock deal to acquire Bio-Reference Laboratories Inc., of Elmwood Park, New Jersey.

When did opko buy GeneDx?

STAMFORD, Conn., May 02, 2022 — Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it has completed the acquisition of GeneDx, LLC (“GeneDx”), a leader in genomic testing and analysis for rare disorders, from OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”).

Is Bioreference laboratories a public company?

How long does it take to get results from BioReference?

Molecular test results will typically be available within 3 days after the sample is received at our facility in New Jersey. Positive 2019-nCoV – Critical.

What does opko Health do?

OPKO Health is a medical test and medication company focused on diagnostics and pharmaceuticals. The company is a publicly traded company on NASDAQ and TASE under the symbol “OPK”.

Where is opko located?

Miami, FL
OPKO Health was founded in October 1991 and is headquartered in Miami, FL.

Who bought GeneDx?

Sema4
Under the terms of the agreement, Sema4 will acquire GeneDx for an upfront payment of $150 million in cash plus 80.0 million shares in Sema4, with up to an additional $150 million revenue-based milestones over the next two years (which will be payable in cash or Sema4 shares at Sema4’s discretion).

Who is bigger quest or labcorp?

For years, Quest was the largest, but LabCorp took over that spot a few years ago. Both companies are noted for growth through acquisition, and 2017 has been a very big year for LabCorp. Since 2008, LabCorp has acquired 19 companies.

Where does labcorp do its testing?

Your specimen is collected for testing in your doctor’s office or at a Labcorp lab – also referred to as a patient service center (PSC).

Why did I receive a check from BioReference Laboratories?

Is NYU BioReference a PCR test?

NYU students, faculty, and staff can get a rapid PCR test on campus to fulfill any testing requirements — or get a discretionary test once per week.

Who owns OPKO Health company?

Dr. Phillip Frost
At OPKO Health, the entrepreneurial acumen of our founder and CEO, Dr. Phillip Frost, has led to the development of a diverse healthcare company flexible enough to adapt to evolving patient needs.

Is OPK a good stock to buy 2021?

Out of 3 analysts, 2 (66.67%) are recommending OPK as a Strong Buy, 0 (0%) are recommending OPK as a Buy, 1 (33.33%) are recommending OPK as a Hold, 0 (0%) are recommending OPK as a Sell, and 0 (0%) are recommending OPK as a Strong Sell.